GT Biopharma, Inc. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that its common stock…
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par
How this was made
The 30-second read
Why it matters
Regaining compliance removes a listing threat, potentially stabilizing the share price.
Market read
The filing is a primary disclosure of compliance restoration, a material corporate event for GTBP.
What to watch
The company’s cash runway and pipeline progress remain critical.
Background
GT Biopharma had been below the $1.00 bid price for 30 days, prompting a Nasdaq notice and a 180‑day compliance period.
Ticker impact
GT Biopharma regained Nasdaq minimum bid price compliance on Sep 22, 2026 after meeting the $1.00 threshold.
Potential modest upside as investors view compliance positively.
Regaining compliance removes a delisting risk, which is a material catalyst for a micro‑cap stock.
Market effects
Other biotech micro‑caps may see similar compliance scrutiny.
Limited to U.S. OTC/ Nasdaq‑listed small caps.
Low
Counterpoint
Some investors may still be wary of underlying business fundamentals despite compliance.
Key entities
- companyGT Biopharma, Inc.
Biopharmaceutical company listed under ticker GTBP.
- regulatorNasdaq Listing Qualifications Staff
Entity that monitors and enforces Nasdaq listing rules.
